These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


406 related items for PubMed ID: 33075480

  • 1. Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.
    Arnsten AFT.
    Neurobiol Learn Mem; 2020 Dec; 176():107327. PubMed ID: 33075480
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals.
    Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AF.
    Learn Mem; 2006 Dec; 13(6):770-6. PubMed ID: 17101879
    [Abstract] [Full Text] [Related]

  • 4. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.
    Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF.
    J Neurosci; 2002 Oct 01; 22(19):8771-7. PubMed ID: 12351753
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions.
    Fukuyama K, Nakano T, Shiroyama T, Okada M.
    Int J Mol Sci; 2021 Apr 16; 22(8):. PubMed ID: 33923533
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
    Alamo C, López-Muñoz F, Sánchez-García J.
    Actas Esp Psiquiatr; 2016 May 16; 44(3):107-12. PubMed ID: 27254403
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
    Arnsten AF, Pliszka SR.
    Pharmacol Biochem Behav; 2011 Aug 16; 99(2):211-6. PubMed ID: 21295057
    [Abstract] [Full Text] [Related]

  • 12. Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat.
    Ji XH, Ji JZ, Zhang H, Li BM.
    Neuropsychopharmacology; 2008 Aug 16; 33(9):2263-71. PubMed ID: 17957212
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.
    Arnsten AF.
    Expert Rev Neurother; 2010 Oct 16; 10(10):1595-605. PubMed ID: 20925474
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.
    Schmeichel BE, Zemlan FP, Berridge CW.
    Neuropharmacology; 2013 Jan 16; 64(1):321-8. PubMed ID: 22796428
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction.
    Arnsten AF.
    CNS Drugs; 2009 Jan 16; 23 Suppl 1():33-41. PubMed ID: 19621976
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.